SCHEMBL1162746

SCHEMBL1162746

Cc1cn(-c2ccc(C#N)cc2)cn1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2D6 P10635 1/20 0.55
CYP19A1 P11511 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
CYP2A6 P11509 2/20 0.47
CYP2E1 P05181 1/20 0.47
EP300 Q09472 2/20 0.43
PDE4A P27815 1/20 0.43
PDE4B Q07343 1/20 0.43
PDE4C Q08493 1/20 0.43
PDE4D Q08499 1/20 0.43
ALDH1A1 P00352 2/20 0.42
GRM5 P41594 2/20 0.41
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
PSEN1 P49768 2/20 0.39
PSEN2 P49810 2/20 0.39
APH1B Q8WW43 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27985278 0.84 CYP1A2 (0.65) CYP1A2CYP3A4CYP2D6CYP19A1CYP2C9
SCHEMBL3040182 0.82 CYP1A2 (0.55) CYP1A2CYP3A4CYP2D6CYP19A1CYP2C9
SCHEMBL25581837 0.80 GRM5 (0.62) CYP1A2CYP3A4CYP2D6CYP19A1CYP2C9
SCHEMBL2285981 0.79 CYP1A2 (0.59) CYP1A2CYP3A4CYP2D6CYP19A1CYP2C9
SCHEMBL25513083 0.79 XDH (0.40) GRM5OTUD7BCYP11B2USP30KDM4E
SCHEMBL13530933 0.78 NR2E1 (0.42) CYP1A2CYP3A4CYP2D6CYP19A1CYP2C9
SCHEMBL1461548 0.78 KDM4E (0.57) CYP1A2CYP3A4CYP2D6CYP19A1CYP2C9
SCHEMBL3953088 0.78 EP300 (0.46) CYP1A2CYP3A4CYP2D6CYP19A1CYP2C9
Hydrochloric Acid SCHEMBL25197219 0.77 XDH (0.39) GRM5OTUD7BCYP11B2USP30KDM4E
SCHEMBL10664108 0.77 NPC1 (0.53) GRM5OTUD7BUSP30

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020141439-A1 HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) 2020-07-09 WO disclosed
EP-1893572-B1 FACTOR XA INHIBITORS MILLENNIUM PHARM INC (US) 2016-12-14 EP disclosed
US-8377974-B2 Factor Xa inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2013-02-19 US disclosed
US-20120178733-A1 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2012-07-12 US disclosed
US-8153670-B2 Factor Xa inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2012-04-10 US disclosed
US-20090298806-A1 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. 2009-12-03 US disclosed
US-7521470-B2 Factor Xa inhibitors MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-04-21 US disclosed
WO-2006002099-A2 FACTOR XA INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298806-A1 FACTOR XA INHIBITORS TFPI, F12, F11 CYP1A2 117/4885CYP3A4 120/4885CYP2D6 189/4885
US-20120178733-A1 FACTOR XA INHIBITORS TFPI, F12, F11 CYP1A2 117/4885CYP3A4 120/4885CYP2D6 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.